These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38005828)

  • 1. Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19.
    Rasmussen HB; Hansen PR
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.
    Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS
    Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
    Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
    Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
    Xie Y; Choi T; Al-Aly Z
    BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
    Kikuchi K; Nangaku M; Ryuzaki M; Yamakawa T; Ota Y; Hanafusa N; Sakai K; Kanno Y; Ando R; Shinoda T; Wakino S; Nakamoto H; Takemoto Y; Akizawa T;
    Ther Apher Dial; 2023 Dec; 27(6):1064-1069. PubMed ID: 37395555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molnupiravir for the treatment of COVID-19.
    Santani BG; LeBlanc BW; Thakare RP
    Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
    Khiali S; Khani E; B Rouy S; Entezari-Maleki T
    Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.